Veyonda Abstract Published at ASCO Annual Meeting 2022

Noxopharm Limited. ABN 50 608 966 123 Level 20, Tower A, The Zenith, 821 Pacific Highway, Chatswood NSW 2067 AUSTRALIA ASCO Abstract Confirms the Immunomodulatory Properties of Veyonda® Highlights • ASCO (American Society of Clinical Oncology) published research abstract relating to idronoxil, the active ingredient in Veyonda® • Idronoxil in combination with the chemotherapy agent cisplatin found to change the tumour environment from ‘cold’ to ‘hot’ • Combination treatment found to be more effective against nasopharyngeal carcinoma cells than cisplatin alone Sydney 27 May 2022: Australian biotech Noxopharm Limited (ASX:NOX) announces that the prestigious ASCO (American Society of Clinical Oncology) Annual Meeting 2022 has published an abstract summarising scientific research related to idronoxil, the active ingredient in Noxopharm’s lead drug candidate Veyonda®. The research was conducted at The University of Hong Kong and focused on nasopharyngeal carcinoma, a cancer that is common in Southern China. The study examined the effect of idronoxil in combination with standard chemotherapy drug cisplatin on cell lines established from human nasopharyngeal tumours and in animal models of that cancer type. The findings confirmed that using idronoxil in combination with cisplatin could change the tumour environment, allowing a larger number of immune cells to infiltrate the tumours compared to the control. The level of immune cell infiltration, measured as the number of immune cells in the tumour vs blood, increased significantly by 67% in the combination treatment compared to the control group. Turning ‘cold’ tumours to ‘hot’ by enabling the immune cells to reach the tumour cells, is an important objective in current cancer therapy developments as it can increase the anti-cancer effect of commonly used cancer drugs. These results further validate the rationale behind Noxopharm’s clinical trials CEP-2 and IONIC which are currently ongoing in the USA and Australia. Lead researcher, Prof. Dora Kwong, Clinical Professor in the Department of Clinical Oncology at the University of Hong Kong stated ‘Our work has been reviewed by the most eminent oncologists and oncology researchers to be accepted as an online publication as part of ASCO 2022, the leading clinical oncology meeting worldwide. It is my hope that our work will contribute to the development of new treatments for nasopharyngeal carcinoma’. The full study is currently being written up and will be submitted to a highly ranked peer-reviewed scientific journal for publication. -ENDS- Noxopharm Limited. ABN 50 608 966 123 Level 20, Tower A, The Zenith, 821 Pacific Highway, Chatswood NSW 2067 AUSTRALIA About ASCO 2022 The ASCO Annual Meeting is the world’s largest global forum for the presentation of scientific research and state-of-the-art education in clinical oncology. This year, the event is expected to attract about 40,000 attendees from around the world, both online and in-person: oncology physicians, industry representatives, scientific researchers, patient advocates and investment analysts. Clinical trial results and oncology research updates presented at ASCO's Annual Meeting represent the significant progress made each year in the fi ght against cancer. For additional information about ASCO 2022 please visit: https://www.asco.org/ About Noxopharm Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation. It has three active drug development programs: its lead clinical-stage drug candidate Veyonda®, plus two innovative technology platforms, which provide the basis for active development of a growing pipeline of new proprietary drugs. Noxopharm also has a major shareholding in the US biotech company Nyrada Inc (ASX:NYR), which is active in the areas of drug development for cardiovascular and neurological diseases. To learn more, please visit: noxopharm.com Investor, Corporate & Media enquiries: Prue Kelly M: 0459 022 445 E: [email protected] Company Secretary: David Franks T: +61 2 8072 1400 E: [email protected] Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors. Forward Looking Statements This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward- looking statement.

The release as fetched from its publisher. noxopharm.com ↗